Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

doi:10.3748/wjg.v29.i13.2015

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3411)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

163

WORD

HTML

1875

Figures (1-3)

340

Tables (1-7)

274

Sum=2706

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

178

Download

527

Sum=705

Apr 7, 2023 (publication date) through Oct 13, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Apr 7, 2023; 29(13): 2015-2033
Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.2015

Table 4 Treatment effectiveness according to regimen, calculated as per protocol analysis

Regimen	SVR PP, n (%)
All regimens	3271/3442 (95)
OBV/PTV/(r ± DSV ± RBV)	1052/1076 (97.8)
LDV/(SOF ± RBV)	748/778 (96.1)
GZR/(EBR ± RBV)	387/398 (97.2)
VEL/(SOF ± RBV)	477/521 (91.6)
GLE/PIB	420/435 (96.6)
GLE/PIB/(SOF + RBV)	2/2 (100)
ASV + DCV	47/55 (85.5)
SOF + DCV ± RBV	21/21 (100)
SOF + RBV	105/144 (72.9)
SOF + SMV ± RBV	5/5 (100)
VOX/VEL/SOF	7/7 (100)

PP: Per protocol; SVR: Sustained virological response; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir; RBV: Ribavirin; LDV: Ledipasvir; SOF: Sofosbuvir; GZR: Grazoprevir; EBR: Elbasvir; VEL: Velpatasvir; GLE: Glecaprevir; PIB: Pibrentasvir; ASV: Asunaprevir; DCV: Daclatasvir; SMV: Simeprevir; VOX: Voxilaprevir.

Citation: Brzdęk M, Zarębska-Michaluk D, Rzymski P, Lorenc B, Kazek A, Tudrujek-Zdunek M, Janocha-Litwin J, Mazur W, Dybowska D, Berak H, Parfieniuk-Kowerda A, Klapaczyński J, Sitko M, Sobala-Szczygieł B, Piekarska A, Flisiak R. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. World J Gastroenterol 2023; 29(13): 2015-2033
URL: https://www.wjgnet.com/1007-9327/full/v29/i13/2015.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i13.2015